Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2022 · View financials
Decision snapshot: VNDA stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs CTXR P/S.
Implied fair value · at VNDA's multiple
Needs VNDA P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VNDA FY 2025 (ended Dec 31, 2025) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
VANDA PHARMACEUTICALS INC. · implied price per share
Bear
-$5.92
Base
-$6.96
Bull
-$8.01
Citius Pharmaceuticals, Inc. · implied price per share
Bear
$0.09
Base
$0.11
Bull
$0.13
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.24x
0.01x
Net debt / EBITDA
Leverage against operating earnings
0.82x
0.09x
Cash and equivalents
Liquid reserves on the balance sheet
$185.77M
$4.25M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
VNDA vs SUPN
CATALYST PHARMACEUTICALS, INC.
VNDA vs CPRX
Harmony Biosciences Holdings, Inc.
VNDA vs HRMY
ELI LILLY & Co
VNDA vs LLY
INCYTE CORP
VNDA vs INCY
Sarepta Therapeutics, Inc.
VNDA vs SRPT
Zomedica Corp.
VNDA vs ZOM
Aquestive Therapeutics, Inc.
VNDA vs AQST
ACADIA PHARMACEUTICALS INC
VNDA vs ACAD
AMGEN INC
VNDA vs AMGN
GILEAD SCIENCES, INC.
VNDA vs GILD
AbbVie Inc.
VNDA vs ABBV
$78.18M
$1.00M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
